Regeneron (REGN) has released an update to notify the public and investors about its officers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals, Inc. has executed its CFO succession plan by appointing Christopher Fenimore as the new Senior Vice President, Finance and Chief Financial Officer, replacing the retiring Robert E. Landry. Concurrently, Jason Pitofsky was promoted to Vice President, Controller. These appointments are effective the day after the company’s annual report filing, expected on February 5, 2024. Fenimore’s compensation includes a base salary increase to $660,000 and an equity award worth $5 million, while Pitofsky’s compensation remains unchanged.
For further insights into REGN corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.